150 related articles for article (PubMed ID: 19232278)
21. Functional heartburn: definition and management strategies.
Zerbib F; Bruley des Varannes S; Simon M; Galmiche JP
Curr Gastroenterol Rep; 2012 Jun; 14(3):181-8. PubMed ID: 22451252
[TBL] [Abstract][Full Text] [Related]
22. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
[TBL] [Abstract][Full Text] [Related]
23. Evolving issues in the management of reflux disease?
Yuan Y; Hunt RH
Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
[TBL] [Abstract][Full Text] [Related]
24. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
Lee KJ; Kwon HC; Cheong JY; Cho SW
Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
Dickman R; Schiff E; Holland A; Wright C; Sarela SR; Han B; Fass R
Aliment Pharmacol Ther; 2007 Nov; 26(10):1333-44. PubMed ID: 17875198
[TBL] [Abstract][Full Text] [Related]
26. Extraesophageal and atypical manifestations of GERD.
Wong WM; Fass R
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S33-43. PubMed ID: 15324380
[TBL] [Abstract][Full Text] [Related]
27. Esophageal hypersensitivity may be a major cause of heartburn.
Rodriguez-Stanley S; Robinson M; Earnest DL; Greenwood-Van Meerveld B; Miner PB
Am J Gastroenterol; 1999 Mar; 94(3):628-31. PubMed ID: 10086642
[TBL] [Abstract][Full Text] [Related]
28. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid.
Shapiro M; Green C; Bautista JM; Peru RL; Malagon IB; Corvo M; Risner-Adler S; Beeler JN; Tuchinsky I; Fass R
Am J Gastroenterol; 2006 May; 101(5):1084-91. PubMed ID: 16573776
[TBL] [Abstract][Full Text] [Related]
29. Non-erosive reflux disease--some clinical case scenarios.
Heading RC
Digestion; 2008; 78 Suppl 1():55-60. PubMed ID: 18832841
[TBL] [Abstract][Full Text] [Related]
30. Stopping proton pump inhibitor use may cause heartburn.
Mayo Clin Health Lett; 2010 Jan; 28(1):4. PubMed ID: 20148484
[No Abstract] [Full Text] [Related]
31. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
Tack J; Koek G; Demedts I; Sifrim D; Janssens J
Am J Gastroenterol; 2004 Jun; 99(6):981-8. PubMed ID: 15180713
[TBL] [Abstract][Full Text] [Related]
32. [Heartburn: you can choose to support in the short term].
Camain JY; Wiesel PH; Peytremann-Bridevaux I
Rev Med Suisse; 2011 May; 7(296):1169. PubMed ID: 21721208
[No Abstract] [Full Text] [Related]
33. Diagnosis and treatment of heartburn. An update on therapies.
Wright W
Adv Nurse Pract; 2010 Apr; 18(4):24-9; quiz 30. PubMed ID: 20486300
[No Abstract] [Full Text] [Related]
34. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome.
Rubenstein JH; Nojkov B; Korsnes S; Adlis SA; Shaw MJ; Weinman B; Inadomi JM; Saad R; Chey WD
Aliment Pharmacol Ther; 2007 Aug; 26(3):443-52. PubMed ID: 17635379
[TBL] [Abstract][Full Text] [Related]
35. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
36. When asking the right question, conventional pH-monitoring provides the right answer.
Tutuian R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):9-10. PubMed ID: 19337626
[No Abstract] [Full Text] [Related]
37. Segmental changes in smooth muscle contraction as a predictive factor of the response to high-dose proton pump inhibitor treatment in patients with functional chest pain.
Lee H; Park JC; Shin SK; Lee SK; Lee YC
J Gastroenterol Hepatol; 2012 Jul; 27(7):1192-9. PubMed ID: 22413883
[TBL] [Abstract][Full Text] [Related]
38. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy.
Blonski W; Vela MF; Castell DO
J Clin Gastroenterol; 2009 Oct; 43(9):816-20. PubMed ID: 19398927
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
40. [Proton pump inhibitors according to need. Always for heartburn].
Labenz J
MMW Fortschr Med; 2002 Jun; 144(23):34-7. PubMed ID: 12119901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
